Cours Lexicon Pharmaceuticals, Inc. Nasdaq
Actions
US5288721047
Recherche biotechnologique et médicale
CA 2024 * | 24,2 M 21,92 M | CA 2025 * | 83,79 M 75,91 M | Capitalisation | 441 M 399 M |
---|---|---|---|---|---|
Résultat net 2024 * | -200 M -181 M | Résultat net 2025 * | -201 M -182 M | VE / CA 2024 * | 18,2 x |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 5,26 x |
PER 2024 * |
-2,34
x | PER 2025 * |
-2,61
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 97,71% |
Dernier transcript sur Lexicon Pharmaceuticals, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 07/07/14 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 01/01/99 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 02/08/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01/02/01 |
Ray Debbane
CHM | Chairman | 69 | 01/08/07 |
Director/Board Member | 65 | 28/08/07 |
Varia. 1 janv. | Capi. | |
---|---|---|
+3,91% | 109 Md | |
+10,87% | 105 Md | |
+1,28% | 22,25 Md | |
-13,14% | 22,09 Md | |
-7,05% | 18,68 Md | |
-38,36% | 17,58 Md | |
-10,66% | 16,85 Md | |
+3,75% | 13,76 Md | |
+36,70% | 12,46 Md |